Join our daily newsletter At The Bell to receive exclusive market insights
- Wellnex Life (WNX) signs agreement to supply its soft gel liquid paracetamol to GLaxoSmithKline (GSK) Consumer Trading Services (CTS)
- A subsidiary of GSK Consumer Healthcare, CSK CTS will retail WNX’s product under its pain relief brand in Australia and New Zealand
- Throughout the three-year agreement, Wellnex will be responsible for manufacturing the products
- WNX CEO George Karafotias says the deal was testament to the work of recently acquired, Brand Solutions Australia, which has been working to secure this agreement
- Shares have been trading grey at 8.2 cents at market open
Wellnex Life (WNX) has signed an agreement to supply its soft gel liquid paracetamol to GlaxoSmithKline (GSK) Consumer Trading Services (CTS).
GSK CTS is a subsidiary of GSK Consumer Healthcare which is one of the world’s largest and leading global consumer healthcare companies known for its brands which include Panadol, Sensodyne, Voltaren, Polident, Centrum, Otrivin and Advil.
Under the new supply agreement, GSK will retail Wellnex’s product under its pain relief brand in Australia and New Zealand.
Throughout the three year agreement, Wellnex will be responsible for manufacturing the products.
According to Wellnex, this agreement is part of its business model to health and wellness products first or fast to the market.
Director of Wellnex Life Zack Bozinovsk said partnering with a subsidiary of a leading healthcare company is exciting, and WNX looks forward to working with GSK.
CEO George Karafotias added that the deal was testament in particular to the work of its recently acquired company, Brand Solutions Australia, which has reportedly been working with GSK Consumer Healthcare for over 12 months to secure this agreement.
Shares were trading grey at 8.2 cents at market open.
